Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 168

1.

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.

Yaish H, Matsushita T, Belhani M, Jiménez-Yuste V, Kavakli K, Korsholm L, Matytsina I, Philipp C, Reichwald K, Wu R.

Haemophilia. 2019 Dec 9. doi: 10.1111/hae.13883. [Epub ahead of print]

PMID:
31816159
2.

A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

Young G, Liesner R, Chang TY, Sidonio RF, Oldenburg J, Jiménez-Yuste V, Mahlangu JN, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME.

Blood. 2019 Oct 10. pii: blood.2019001869. doi: 10.1182/blood.2019001869. [Epub ahead of print]

PMID:
31697801
3.

Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement.

Tiede A, Giangrande P, Teitel J, Amano K, Benson G, Nemes L, Jiménez-Yuste V, d'Oiron R, Benchikh El Fegoun S, Kessler CM.

Haemophilia. 2019 Nov;25(6):969-978. doi: 10.1111/hae.13844. Epub 2019 Sep 13.

PMID:
31517435
4.

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J.

Blood. 2019 Nov 28;134(22):1973-1982. doi: 10.1182/blood.2019001542.

PMID:
31444162
5.

Health education and empowerment in adult patients with haemophilia.

De la Corte-Rodriguez H, Rodriguez-Merchan EC, Alvarez-Roman T, Martin-Salces M, Garcia-Barcenilla S, Jimenez-Yuste V.

Expert Rev Hematol. 2019 Nov;12(11):989-995. doi: 10.1080/17474086.2019.1650640. Epub 2019 Aug 8.

PMID:
31393181
6.

Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.

Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Tosetto A, Wheeler A, Santagostino E.

Res Pract Thromb Haemost. 2019 Jun 11;3(3):542-554. doi: 10.1002/rth2.12220. eCollection 2019 Jul.

7.

[Haemophilia: Reasons for visits to the paediatric emergency department].

García Sánchez P, Martín Sánchez J, Rivas Pollmar MI, Álvarez Román MT, Jiménez Yuste V.

An Pediatr (Barc). 2019 Dec;91(6):394-400. doi: 10.1016/j.anpedi.2019.04.017. Epub 2019 Jun 3. Spanish.

8.

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.

Oldenburg J, Hay CRM, Jiménez-Yuste V, Peyvandi F, Schved JF, Szamosi J, Winding B, Lethagen S.

BMJ Open. 2019 May 30;9(5):e028012. doi: 10.1136/bmjopen-2018-028012.

9.

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.

Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jiménez-Yuste V.

Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16.

PMID:
31003963
10.

Accelerating recovery from acute hemarthrosis in patients with hemophilia: the role of joint aspiration.

De la Corte-Rodriguez H, Rodriguez-Merchan EC, Alvarez-Roman MT, Martin-Salces M, Romero-Garrido JA, Jimenez-Yuste V.

Blood Coagul Fibrinolysis. 2019 Apr;30(3):111-119. doi: 10.1097/MBC.0000000000000803.

PMID:
30958454
11.

Rapid and sustained immune tolerance to inhibitors induced by a plasma-derived, VWF-containing FVIII concentrate.

Santagostino E, Rangarajan S, Oldenburg J, Peiró-Jordan R, Jiménez-Yuste V.

Haemophilia. 2019 Mar;25(2):e110-e113. doi: 10.1111/hae.13676. Epub 2019 Feb 20. No abstract available.

PMID:
30786119
12.

Inhibitors: A Need for Eradication?

Santagostino E, Young G, Escuriola Ettingshausen C, Jimenez-Yuste V, Carcao M.

Acta Haematol. 2019;141(3):151-155. doi: 10.1159/000495454. Epub 2019 Feb 15. Review.

13.

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB.

Blood Transfus. 2019 Sep;17(5):391-398. doi: 10.2450/2019.0183-18. Epub 2019 Feb 4.

14.

Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists.

Justo Sanz R, Monzón Manzano E, Fernández Bello I, Teresa Álvarez Román M, Martín Salces M, Rivas Pollmar MI, Jiménez Yuste V, Butta NV.

Thromb Haemost. 2019 Apr;119(4):645-659. doi: 10.1055/s-0039-1678706. Epub 2019 Feb 11.

PMID:
30743272
15.

Hindfoot malalignment in adults with haemophilic ankle arthropathy: The importance of early detection and orthotic treatment.

De la Corte-Rodriguez H, Rodriguez-Merchan EC, Alvarez-Roman MT, Martin-Salces M, Jimenez-Yuste V.

Haemophilia. 2019 May;25(3):500-508. doi: 10.1111/hae.13680. Epub 2019 Jan 21.

PMID:
30664313
16.

Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.

Fernández-Bello I, Rode F, Álvarez-Román MT, Butta NV, Rivas-Muñoz S, Hernández-Moreno AL, de la Corte-Rodríguez H, Martín-Salces M, Larsen LF, Jiménez-Yuste V.

Eur J Pharm Sci. 2019 Feb 1;128:215-221. doi: 10.1016/j.ejps.2018.12.003. Epub 2018 Dec 7.

PMID:
30529268
17.

Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score.

Jiménez-Yuste V, Álvarez-Román MT, Martín-Salces M, De la Corte-Rodríguez H, Altisent C, Parra R, Núñez R, Pérez R, García-Candel F, Bonanad S, Querol F, Alonso N, Fernández-Mosteirín N, López-Ansoar E, García-Frade LJ, Bermejo N, Pérez-González N, Gutiérrez-Pimentel MJ, Martinoli C, Fernández-Arias I, Kim HK.

Haemophilia. 2019 Jan;25(1):144-153. doi: 10.1111/hae.13628. Epub 2018 Nov 16.

PMID:
30444298
18.

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.

Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, Morfini M, Zupančić-Šalek S, Santagostino E.

Eur J Haematol. 2019 Feb;102(2):111-122. doi: 10.1111/ejh.13193. Epub 2018 Dec 6. Review.

PMID:
30411401
19.

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.

Eichler H, Angchaisuksiri P, Kavakli K, Knoebl P, Windyga J, Jiménez-Yuste V, Harder Delff P, Chowdary P.

Haemophilia. 2019 Jan;25(1):60-66. doi: 10.1111/hae.13627. Epub 2018 Nov 8.

PMID:
30408848
20.

Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA.

Borràs N, Orriols G, Batlle J, Pérez-Rodríguez A, Fidalgo T, Martinho P, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Parra R, Altisent C, Cid AR, Bonanad S, Cabrera N, Moret A, Mingot-Castellano ME, Navarro N, Pérez-Montes R, Marcellin S, Moreto A, Herrero S, Soto I, Fernández-Mosteirín N, Jiménez-Yuste V, Alonso N, de Andrés-Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Quismondo NC, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, Tenorio JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobón M, Aguilar C, Vidal F, Corrales I.

Haematologica. 2019 Mar;104(3):587-598. doi: 10.3324/haematol.2018.203166. Epub 2018 Oct 25.

Supplemental Content

Loading ...
Support Center